# Sermorelin

Canonical source: https://retacompare.com/encyclopedia/sermorelin

GHRH receptor agonist. Stimulates pituitary somatotrophs to release endogenous growth hormone in pulsatile fashion.

Reference facts

Also known asGHRH (1-29), GRF 1-29CategoryGrowth Hormone & GhrelinMechanism of actionGHRH receptor agonist. Stimulates pituitary somatotrophs to release endogenous growth hormone in pulsatile fashion.TargetsGHRHRIndications under research or approvedPediatric growth hormone deficiency (formerly approved as Geref); off-label adult anti-aging researchRegulatory status (reference entry)FDA approval withdrawn 2008 (commercial reasons); compounded as research peptideHalf-life~10–20 minutesSequenceYADAIFTNSYRKVLGQLSARKLLQDIMSRSequence notes29-residue N-terminal fragment of human growth hormone-releasing hormone (GHRH 1-29 NH2). C-terminal amide.Molecular weight (Da)3358PDB accession1HOZOriginator / sponsorOriginally Serono (Geref); now compounding pharmaciesFirst reported1980OriginSynthesized from the GHRH sequence isolated by Roger Guillemin and Wylie Vale (Nobel laureates).
    Primary References

Geref FDA approval history


    Explore research articles about Sermorelin


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- Geref FDA approval history: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019863